496 related articles for article (PubMed ID: 18974746)
1. Patent watch.
Harrison C
Nat Rev Drug Discov; 2008 Nov; 7(11):882-3. PubMed ID: 18974746
[No Abstract] [Full Text] [Related]
2. Balancing innovation, access, and profits--market exclusivity for biologics.
Engelberg AB; Kesselheim AS; Avorn J
N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525
[No Abstract] [Full Text] [Related]
3. Patent watch: EPO rejects reach through claims.
Nat Rev Drug Discov; 2010 Jan; 9(1):12. PubMed ID: 20043023
[No Abstract] [Full Text] [Related]
4. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
[No Abstract] [Full Text] [Related]
5. The challenge to patent law of pure chemical protein synthesis.
Fellmeth AX
Nat Biotechnol; 2005 May; 23(5):547-9. PubMed ID: 15877067
[No Abstract] [Full Text] [Related]
6. Amgen preserves erythropoietin monopoly for now.
Chahine K
Nat Biotechnol; 2001 Mar; 19(3):188. PubMed ID: 11231519
[No Abstract] [Full Text] [Related]
7. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
8. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
9. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
10. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
Furrow ME
Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
[No Abstract] [Full Text] [Related]
11. Navigating the Hatch-Waxman Act's safe harbor.
Jones PB
Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
[No Abstract] [Full Text] [Related]
12. Overview of the Hatch-Waxman Act and its impact on the drug development process.
Mossinghoff GJ
Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
[No Abstract] [Full Text] [Related]
13. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
14. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
15. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
16. India remains on US trade "priority watch list" for failing to uphold international drug company patents.
Arie S
BMJ; 2013 May; 346():f2949. PubMed ID: 23657189
[No Abstract] [Full Text] [Related]
17. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
18. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
19. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
20. Market exclusivity for biologics.
Wheadon DE
N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
[No Abstract] [Full Text] [Related]
[Next] [New Search]
